Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort
| Autor: | Rodney Theodore, Vaughn Barry, Robert Clark Brown, Maa-Ohui Quarmyne, Wei Dong, Clinton H. Joiner, James Bost, Sonia Anand, Iris Buchanan, Olufolake Adisa, Peter A. Lane |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Pediatrics
medicine.medical_specialty business.industry Thalassemia Retrospective cohort study Hematology Emergency department Hemoglobin levels medicine.disease Sickle cell anemia 03 medical and health sciences Population based cohort 0302 clinical medicine hemic and lymphatic diseases 030220 oncology & carcinogenesis Cohort medicine 030212 general & internal medicine business Pediatric population |
| Zdroj: | American Journal of Hematology. 92:77-81 |
| ISSN: | 0361-8609 |
| DOI: | 10.1002/ajh.24587 |
| Popis: | The clinical efficacy of hydroxyurea in patients with sickle cell anemia (SCA) has been well established. However, data about its clinical effectiveness in practice is limited. We evaluated the clinical effectiveness of hydroxyurea in a large pediatric population using a retrospective cohort, pre-post treatment study design to control for disease severity selection bias. The cohort included children with SCA (SS, Sβ0 thalassemia) who received care at Children's Healthcare of Atlanta (CHOA) and who initiated hydroxyurea in 2009-2011. Children on chronic transfusions, or children with inadequate follow up data and/or children who had taken hydroxyurea in the 3 years prior were excluded. For each patient healthcare utilization, laboratory values, and clinical outcomes for the 2-year period prior to hydroxyurea initiation were compared to those 2 years after initiation. Of 211 children with SCA who initiated hydroxyurea in 2009-2011, 134 met eligibility criteria. After initiation of hydroxyurea, rates of hospitalizations, pain encounters, and emergency department visits were reduced by 47% ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text